BioNexus Gene Lab Corp (BGLC) concluded trading on Thursday at a closing price of $6.63, with 6.65 million shares of worth about $44.11 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 91.62% during that period and on July 17, 2025 the price saw a gain of about 56.00%. Currently the company’s common shares owned by public are about 1.80M shares, out of which, 1.17M shares are available for trading.
Stock saw a price change of 9.77% in past 5 days and over the past one month there was a price change of 123.61%. Year-to-date (YTD), BGLC shares are showing a performance of 25.00% which increased to 137.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.01 but also hit the highest price of $15.60 during that period. The average intraday trading volume for BioNexus Gene Lab Corp shares is 989.90K. The stock is currently trading 40.11% above its 20-day simple moving average (SMA20), while that difference is up 77.34% for SMA50 and it goes to 94.38% higher than SMA200.
BioNexus Gene Lab Corp (NASDAQ: BGLC) currently have 1.80M outstanding shares and institutions hold larger chunk of about 0.88% of that.
The stock has a current market capitalization of $11.91M and its 3Y-monthly beta is at 1.80. It has posted earnings per share of -$1.18 in the same period. It has Quick Ratio of 3.44 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BGLC, volatility over the week remained 26.38% while standing at 19.91% over the month.
Analysts are in expectations that BioNexus Gene Lab Corp (BGLC) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same.